The Role of Tumor Mutational Burden in Lung Cancer

Geoffrey R. Oxnard, MD; Lauren L. Ritterhouse, MD, PhD

Video Categories: PMO Interview with the Innovator Series: Volume 12 and Video Library

Drs. Goeffrey Oxnard and Lauren Ritterhouse discuss the need for validation and standardization of Tumor Mutational Burden to make it a robust biomarker, in conjunction with PD-L1, in selecting immunotherapy for their lung cancer patients.

Related Videos

July 29, 2015

Precision Medicine’s Impact on Patient Care

Dr. S. Yosuf Zafar provides an overview of the advancement of precision medicine and points out the importance of making sure treatment decisions are in line with the patient’s goals.

February 11, 2013

PMO Interview with the Innovator Series: Volume 5

Michael Pellini, President and Chief Executive Officer of Foundation Medicine, offers a definition of personalized medicine in this new video series from Personalized Medicine in Oncology.